Abstract

The effects of cyclic AMP (cAMP)-related compounds on in vivo [ 3H]SCH 23390 binding to striatal dopamine D 1 receptors were investigated using autoradiography in order to clarify the possible regulation of the cAMP-dependent mechanisms in the in vivo ligand–receptor bindings in the living brain. Intrastriatal infusion of the cAMP analogue, N6,2′- O-dibutyryl-cyclic AMP (db-cAMP; 5, 25 and 100 nmol/side) produced a dose-dependent increase of in vivo [ 3H]SCH 23390 binding in conscious rats. This increasing effect of [ 3H]SCH 23390 binding completely disappeared by 6 h after the infusion of db-cAMP. A similar increase of in vivo [ 3H]SCH 23390 binding to striatal D 1 receptors was also observed by intrastriatal injection of 8-bromo-cyclic AMP (8Br-cAMP, 100 nmol/side). Pretreatment with Rp-cyclic AMP triethylamine (Rp-cAMPS, 100 nmol/side), an inhibitor of the cAMP-dependent protein kinase (PKA), completely blocked the increasing effect of [ 3H]SCH 23390 binding induced by db-cAMP. In contrast, in vitro [ 3H]SCH 23390 binding was not significantly altered by intrastriatal infusion of db-cAMP, which indicated that the maximum number of binding sites ( B max) for D 1 receptors was not changed. The kinetic analysis employed the graphical method indicated that a db-cAMP-induced increase of in vivo [ 3H]SCH 23390 binding was mainly due to an increase in the bimolecular association rate constant ( k on). These results strongly indicate that the PKA-mediated phosphorylation may play a pivotal role in the regulating the in vivo [ 3H]SCH 23390 dopamine D 1 receptor binding in intact rat brain.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call